Venus concept announces first patient treatment in study evaluating the safety and efficacy of aime™ next generation robotic technology for the treatment of moderate to severe facial wrinkles

Toronto, april 25, 2022 (globe newswire) -- venus concept inc. (“venus concept” or the “company”) (nasdaq: vero), a global medical aesthetic technology leader, today announced that the first patient has been treated in a u.s. investigational device exemption (ide) clinical study evaluating the safety and efficacy of the company's aime™ next generation robotic technology for the treatment of moderate to severe facial wrinkles. aime is a robotic platform designed to provide micro-coring for medical aesthetic applications.
VERO Ratings Summary
VERO Quant Ranking